NCT02447419 Study to Evaluate the Safety and Efficacy of Gefitinib, in Subjects With EFGR Amplification Refractory Solid Tumors Status COMPLETED Phase PHASE2
NCT02446431 Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence Status RECRUITING Phase EARLY_PHASE1
NCT02441543 Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus Status COMPLETED Phase N/A
NCT02428036 A Study of TBI-1401(HF10) in Patients With Solid Tumors With Superficial Lesions Status COMPLETED Phase PHASE1
NCT02423343 A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma Status COMPLETED Phase PHASE1/PHASE2
NCT02414516 A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors Status UNKNOWN Phase PHASE1
NCT02412462 Phase I Dose Escalation Study of AB-16B5 in Subjects With an Advanced Solid Malignancy Status COMPLETED Phase PHASE1
NCT02393248 Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Status TERMINATED Phase PHASE1/PHASE2
NCT02355535 Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1 Status COMPLETED Phase PHASE1
NCT02352844 Everolimus in Patients With Advanced Solid Malignancies With TSC1, TSC2, NF1, NF2, or STK11 Mutations Status COMPLETED Phase PHASE2
NCT02332668 A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) Status RECRUITING Phase PHASE1/PHASE2
NCT02285738 Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis Status COMPLETED Phase EARLY_PHASE1
NCT02278250 First in Human Study of M4344 in Participants With Advanced Solid Tumors Status COMPLETED Phase PHASE1
NCT02274610 Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer Status COMPLETED Phase PHASE1
NCT02273739 Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation Status COMPLETED Phase PHASE1/PHASE2
NCT02264613 ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Status COMPLETED Phase PHASE1/PHASE2
NCT02250170 Safety and Biomarker of OPB-111077 in Subjects With Advanced Solid Tumor Status COMPLETED Phase PHASE1